International Conference Centre,
Geneva Switzerland - March 26-29, 2014

Leading scientists will discuss new targets and drugs for the treatment of Alzheimer’s disease and novel approaches to current therapy. An oral communication session will be open to young scientists.

We expect approximately 1500 participants, mostly neurologists, psychiatrists, geriatricians and pharmacologists..


  • • Drug Discovery and Treatment Development
  • • New Preclinical Models of Alzheimer’s Disease
  • • Clinical Trials on Alzheimer’s Disease: New Designs and Measures
  • • Early Diagnosis of Alzheimer’s Disease
  • • Advances in Brain Imaging and Biomarkers
  • • Emerging Novel Therapeutic Targets
  • • Preventive Trials of Alzheimer’s Disease
  • • What is New in Immunization?
  • • Tau Pathology and Tau-Focused Therapy: What’s New?

Core Supporters:
Eli Lilly and Company
F. Hoffmann-La Roche
GE Healthcare

Axon Neuroscience SE
EnVivo Pharmaceuticals
Nutricia Advanced Medical Nutrition
TauRx Pharmaceuticals Ltd
Vifor Pharma Ltd
Worldwide Clinical Trials, USA

Course Directors

Ezio Giacobini, MD, PhD, Geneva
Gabriel Gold, MD, Geneva
Southern Illinois University School of Medicine, Springfield, Illinois, USA
University of Geneva Faculty of Medicine, Geneva, Switzerland
Geneva University Hospitals, Geneva